Outcomes of Transarterial Embolisation (TAE) vs. Transarterial Chemoembolisation (TACE) for Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis

被引:5
|
作者
Lawson, Alexander [1 ]
Kamarajah, Sivesh K. [2 ]
Parente, Alessandro [2 ]
Pufal, Kamil [1 ]
Sundareyan, Ramanivas [3 ]
Pawlik, Timothy M. [4 ]
Ma, Yuk Ting [5 ]
Shah, Tahir [6 ]
Kharkhanis, Salil [3 ]
Dasari, Bobby V. M. [2 ,7 ]
机构
[1] Univ Birmingham, Birmingham Med Sch, Birmingham B15 2TT, England
[2] Queen Elizabeth Hosp, Dept HPB & Liver Transplantat, Birmingham B15 2TH, England
[3] Queen Elizabeth Hosp, Dept Radiol, Birmingham B15 2TH, England
[4] Ohio State Univ, Wexner Med Ctr, Dept Surg, Columbus, OH 43210 USA
[5] Queen Elizabeth Hosp, Dept Oncol, Birmingham B15 2TH, England
[6] Queen Elizabeth Hosp, Liver Unit, Birmingham B15 2TH, England
[7] Univ Birmingham, Inst Immunol & Immunotherapy, Birmingham B15 2TT, England
关键词
hepatocellular carcinoma; transarterial embolisation; transarterial chemoembolisation; TRANSCATHETER ARTERIAL EMBOLIZATION; DRUG-ELUTING BEADS; CONVENTIONAL CHEMOEMBOLIZATION; BLAND EMBOLIZATION; TRIAL;
D O I
10.3390/cancers15123166
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Simple Summary Non-surgical management of hepatocellular carcinoma (HCC) is used for selected patients. Of these management options, transarterial embolisation (TAE) and transarterial chemoembolisation (TACE) are the two main locoregional treatment options. There was no difference in OS among patients treated with TACE/TAE, single versus repeat treatments. Post-procedural adverse effects were higher in the TACE group but were not statistically significant. TACE has a comparable long-term survival and complications profile to TAE for patients with HCC. However, the low-to-moderate quality of current RCTs warrants high-quality RCTs, which are necessary to provide enough evidence to give a definitive answer and inform treatment plans for the future. Although hepatocellular carcinoma is increasingly common, debate exists surrounding the management of patients with unresectable disease comparing transarterial embolisation (TAE) or transarterial chemoembolisation (TACE). This study aimed to compare the outcomes of patients receiving TAE and TACE. A systematic review was performed using PubMed, Medline, Embase, and Cochrane databases to identify randomised controlled trials (RCTs) until August 2021. The primary outcome was overall survival (OS) and the secondary outcomes were progression-free survival (PFS) and adverse events. Five studies with 609 patients were included in the analysis. There was no statistically significant difference in the OS (p = 0.36) and PFS (p = 0.81). There was no difference in OS among patients treated with a single TACE/TAE versus repeat treatments. Post-procedural adverse effects were higher in the TACE group but were not statistically significant. TACE has comparable long-term survival and complications profile to TAE for patients with HCC. However, the low-to-moderate quality of current RCTs warrants high-quality RCTs are necessary to provide enough evidence to give a definitive answer and inform treatment plans for the future.
引用
收藏
页数:11
相关论文
共 50 条
  • [31] Yttrium-90 transarterial radioembolization versus conventional transarterial chemoembolization for patients with hepatocellular carcinoma:a systematic review and meta-analysis
    Yi Yang
    Tongguo Si
    Cancer Biology & Medicine, 2018, (03) : 299 - 310
  • [32] Transarterial chemoembolization combined with lenvatinib versus transarterial chemoembolization combined with sorafenib for unresectable hepatocellular carcinoma: A systematic review and meta-analysis
    Liu, Jun-Ning
    Li, Ji-Jiang
    Yan, Shu
    Zhang, Guang-Nian
    Yi, Peng-Sheng
    FRONTIERS IN ONCOLOGY, 2023, 13
  • [33] Yttrium-90 transarterial radioembolization versus conventional transarterial chemoembolization for patients with hepatocellular carcinoma:a systematic review and meta-analysis
    Yi Yang
    Tongguo Si
    Cancer Biology & Medicine, 2018, 15 (03) : 299 - 310
  • [34] Transarterial chemoembolization combined with lenvatinib versus transarterial chemoembolization combined with sorafenib for unresectable hepatocellular carcinoma: A meta-analysis and systematic review
    Che, X.
    Zhang, W.
    Yin, Y.
    ANNALS OF ONCOLOGY, 2024, 35 : S80 - S80
  • [35] Results of transarterial chemoembolisation (TACE) therapy for hepatocellular carcinoma (HCC) in a general hospital in Singapore
    Kwek, Boon Eu Andrew
    Teo, Eng Kiong
    Fock, Kwong Ming
    Yi-Lyn
    Tan, Jessica
    Chua, Tju Siang
    Poh, Choo Hean
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2006, 21 : A51 - A51
  • [36] Combination of transarterial chemoembolisation (TACE) plus antivirals for the management of hepatitis B-related hepatocellular carcinoma: A systematic review of the literature
    Fouad, Mona
    Abdel-Rahman, Omar
    ARAB JOURNAL OF GASTROENTEROLOGY, 2015, 16 (02) : 40 - 45
  • [37] Meta-analysis of transarterial chemoembolization combined with cryoablation vs transarterial chemoembolization alone for ≥ 5 cm hepatocellular carcinoma
    Cheng, Jie-Fei
    Sun, Qiu-Lian
    Tang, Ling
    Xu, Xin-Jian
    Huang, Xiang-Zhong
    WORLD JOURNAL OF GASTROINTESTINAL ONCOLOGY, 2024, 16 (06) : 2793 - 2803
  • [38] Sorafenib plus transarterial chemoembolization vs sorafenib alone for patients with advanced hepatocellular carcinoma: A systematic review and meta-analysis
    Yang, Hong-Jie
    Ye, Bin
    Liao, Jia-Xu
    Lei, Lei
    Chen, Kai
    WORLD JOURNAL OF HEPATOLOGY, 2024, 16 (01) : 91 - 102
  • [39] Conventional transarterial chemoembolization vs microsphere embolization in hepatocellular carcinoma:A meta-analysis
    Jia-Yan Ni
    Lin-Feng Xu
    Wei-Dong Wang
    Hong-Liang Sun
    Yao-Ting Chen
    World Journal of Gastroenterology, 2014, (45) : 17206 - 17217
  • [40] Conventional transarterial chemoembolization vs microsphere embolization in hepatocellular carcinoma: A meta-analysis
    Ni, Jia-Yan
    Xu, Lin-Feng
    Wang, Wei-Dong
    Sun, Hong-Liang
    Chen, Yao-Ting
    WORLD JOURNAL OF GASTROENTEROLOGY, 2014, 20 (45) : 17206 - 17217